Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer historyMURFF, Harvey J; SPIGEL, David R; SYNGAL, Sapna et al.JAMA, the journal of the American Medical Association. 2004, Vol 292, Num 12, pp 1480-1489, issn 0098-7484, 10 p.Article

Final Survival and Safety Results From a Multicenter, Open-label, Phase 3b Trial of Erlotinib in Patients With Advanced Nonsmall Cell Lung CancerSPIGEL, David R; MING LIN; O'NEILL, Vincent et al.Cancer. 2008, Vol 112, Num 12, pp 2749-2755, issn 0008-543X, 7 p.Article

Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard PathologyGRECO, F. Anthony; LENNINGTON, Wayne J; SPIGEL, David R et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 11, pp 782-790, issn 0027-8874, 9 p.Article

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : A minnie pearl cancer research network studyHAINSWORTH, John D; SPIGEL, David R; LITCHY, Sharlene et al.Journal of clinical oncology. 2006, Vol 24, Num 22, pp 3548-3554, issn 0732-183X, 7 p.Article

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non―Small―Cell Lung CancerSPIGEL, David R; BURRIS, Howard A; BASS, J. David et al.Journal of clinical oncology. 2011, Vol 29, Num 18, pp 2582-2589, issn 0732-183X, 8 p.Article

Bevacizumab and Everolimus in the Treatment of Patients With Metastatic Melanoma: A Phase 2 Trial of the Sarah Cannon Oncology Research ConsortiumHAINSWORTH, John D; INFANTE, Jeffrey R; SPIGEL, David R et al.Cancer. 2010, Vol 116, Num 17, pp 4122-4129, issn 0008-543X, 8 p.Article

Oxaliplatin and Capecitabine in the Treatment of Patients With Recurrent or Refractory Carcinoma of Unknown Primary Site: A Phase 2 Trial of the Sarah Cannon Oncology Research ConsortiumHAINSWORTH, John D; SPIGEL, David R; BURRIS, Howard A et al.Cancer. 2010, Vol 116, Num 10, pp 2448-2454, issn 0008-543X, 7 p.Article

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research InstituteHAINSWORTH, John D; RUBIN, Mark S; SPIGEL, David R et al.Journal of clinical oncology. 2013, Vol 31, Num 2, pp 217-223, issn 0732-183X, 7 p.Article

Combination Therapy With Fludarabine and Rituximab Followed by Alemtuzumab in the First-line Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma : A Phase 2 Trial of the Minnie Pearl Cancer Research NetworkHAINSWORTH, John D; VAZQUEZ, Elizabeth R; SPIGEL, David R et al.Cancer. 2008, Vol 112, Num 6, pp 1288-1295, issn 0008-543X, 8 p.Article

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site : The minnie pearl cancer research networkHAINSWORTH, John D; SPIGEL, David R; FARLEY, Cindy et al.Journal of clinical oncology. 2007, Vol 25, Num 13, pp 1747-1752, issn 0732-183X, 6 p.Article

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non―Small-Cell Lung CancerPATEL, Jyoti D; SOCINSKI, Mark A; GUBA, Susan C et al.Journal of clinical oncology. 2013, Vol 31, Num 34, pp 4349-4357, issn 0732-183X, 9 p.Article

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and BevacizumabSPIGEL, David R; HAINSWORTH, John D; YARDLEY, Denise A et al.Journal of clinical oncology. 2010, Vol 28, Num 1, pp 43-48, issn 0732-183X, 6 p.Article

Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer : A randomized phase 3 trial of the minnie pearl cancer research networkHAINSWORTH, John D; SPIGEL, David R; FARLEY, Cindy et al.Cancer. 2007, Vol 110, Num 9, pp 2027-2034, issn 0008-543X, 8 p.Article

A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancerINFANTE, Jeffrey R; JONES, Suzanne F; BENDELL, Johanna C et al.European journal of cancer (1990). 2011, Vol 47, Num 2, pp 199-205, issn 0959-8049, 7 p.Article

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE TrialSPIGEL, David R; TOWNLEY, Peter M; WATERHOUSE, David M et al.Journal of clinical oncology. 2011, Vol 29, Num 16, pp 2215-2222, issn 0732-183X, 8 p.Article

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung CancerRAMALINGAM, Suresh S; SPIGEL, David R; LIAN LIU et al.Journal of clinical oncology. 2011, Vol 29, Num 34, pp 4574-4580, issn 0732-183X, 7 p.Article

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibHAINSWORTH, John D; SOSMAN, Jeffrey A; SPIGEL, David R et al.Journal of clinical oncology. 2005, Vol 23, Num 31, pp 7889-7896, issn 0732-183X, 8 p.Article

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non―Small-Cell Lung CancerSPIGEL, David R; ERVIN, Thomas J; GOVINDAN, Ramaswamy et al.Journal of clinical oncology. 2013, Vol 31, Num 32, pp 4105-4114, issn 0732-183X, 10 p.Conference Paper

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non―Small-Cell Lung Cancer: MONET 1SCAGLIOTTI, Giorgio V; VYNNYCHENKO, Ihor; DEDIU, Mircea et al.Journal of clinical oncology. 2012, Vol 30, Num 23, pp 2829-2836, issn 0732-183X, 8 p.Article

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerSPIGEL, David R; ANTHONY GRECO, F; BURRIS, Howard A et al.Lung cancer. 2012, Vol 78, Num 1, pp 70-75, issn 0169-5002, 6 p.Article

Safety, Activity, and Immune Correlates of Anti―PD-1 Antibody in CancerTOPALIAN, Suzanne L; HODI, F. Stephen; LEMING, Philip D et al.The New England journal of medicine. 2012, Vol 366, Num 26, pp 2443-2454, issn 0028-4793, 12 p.Article

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung CancerETTINGER, David S; JOTTE, Robert; SALGIA, Ravi et al.Journal of clinical oncology. 2010, Vol 28, Num 15, pp 2598-2603, issn 0732-183X, 6 p.Article

Neuroendocrine Carcinoma of Unknown Primary SiteSPIGEL, David R; HAINSWORTH, John D; GRECO, F. Anthony et al.Seminars in oncology. 2009, Vol 36, Num 1, pp 52-59, issn 0093-7754, 8 p.Article

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabineINFANTE, Jeffrey R; JONES, Suzanne F; BENDELL, Johanna C et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 1, pp 137-144, issn 0344-5704, 8 p.Article

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerSPIGEL, David R; GRECO, F. Anthony; RUBIN, Mark S et al.Lung cancer. 2012, Vol 77, Num 2, pp 359-364, issn 0169-5002, 6 p.Article